Why Gilead Sciences Stock Is Trading Higher Friday

Comments
Loading...
Zinger Key Points

Gilead Sciences, Inc. GILD stock is moving higher Friday on continued strength following the company’s Phase 3 HIV data.

What To Know: On Thursday before the market opened, Gilead announced efficacy data for its possible HIV prevention drug, Lenacapavir. The twice-yearly injectable indicated a 100% efficacy for HIV prevention in cisgender women. This data comes from the company’s Phase 3 PURPOSE 1 trial.

In addition, the trial met its key efficacy endpoints. Specifically, superiority of twice-year lenacapavir compared to once-daily oral Truvada and background HIV incidence.

Related Link: Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

GILD Price Action: At the time of publication, Gilead Sciences stock is trading 1.93% higher at $69.82 per data from Benzinga Pro.

Image: Photo via Shutterstock

GILD Logo
GILDGilead Sciences Inc
$112.500.10%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum95.39
Growth39.44
Quality50.03
Value13.08
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: